BeyondSpring Inc.

NASDAQ:BYSI

Biotechnology

Healthcare
$1.25 +1.58%

+$0.03 today

Market cap
$51.40M
Beta
0.42
P/E (TTM)
-8.7
EPS (TTM)
-$0.19
52W Low $1.18High $3.28

Volume 0.01M

Average 0.02M

BYSI Interest Income

Income earned on cash, deposits, and investments held by the company.

BeyondSpring Inc.NASDAQ: BYSI

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income dips below year-ago levels

Q1 FY2026 interest income of $8K fell 52.9% year over year, behind the +102.9% change in trailing-twelve-month interest income. Sequentially, it fell 42.9% from the prior quarter. Over 3 fiscal years it compounded at -26.3% a year.

Context

  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -52.9% toward the trailing-twelve-month pace of +102.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8K-42.9% QoQ
Last fiscal yearDec 2025
$78K+32.2% YoY
LTMMar 2026
$69K+102.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-52.9%——
1 year+32.2%——
3-year CAGR-26.3%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
78K USD
Year-over-year change
+32.2%
4-year CAGR
-5.5%

Interest Income vs competitors

How BYSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +102.9% is the highest of 7, against a peer median of -46.6%.
  • Over three fiscal years its annual growth of -26.3% compares with a peer median of +3.9%.
BYSI Competitors
Interest Income for BYSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026$3.92M USD-39.0%+6.9%8.7%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$3.66M USD-55.5%-2.5%—
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$2.5M USD+63.9%—63.4%
BMEABiomea Fusion, Inc.LTM Mar 2026$1.84M USD-55.1%+1.0%—
GUTSFractyl Health, Inc. Common StockLTM Mar 2026$1.63M USD-54.1%+24.6%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$1.18M USD-16.9%——
BYSIBeyondSpring Inc.LTM Mar 2026$69K USD+102.9%-26.3%—
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$40K CAD——0.2%
ATYRaTyr Pharma, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding BYSI) —-46.6%+3.9%4.5%

Competitors are the stored peer set for BYSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.35M1.35M000
Cost of Revenue00302K087K
Gross Profit1.35M1.35M(302K)0(87K)
Gross Margin100.0%100.0%———
Research & Development36.89M25.58M7.27M2.64M4.39M
Selling, General & Admin30.7M13.01M7.51M6.11M4.56M
Operating Expenses67.59M38.59M14.78M8.75M8.86M
Depreciation & Amortization61K1.14M302K285K87K
EBITDA(64.49M)(34.96M)(13.62M)(8.48M)(8.54M)
EBITDA Margin-4773.5%-2587.4%———
Operating Income(66.24M)(37.24M)(15.08M)(8.75M)(8.95M)
Operating Margin-4903.0%-2756.4%———
Interest Income98K195K421K59K78K
Interest Expense87K17K000
Other Income / Expenses1.6M1.12M1.16M(15K)320K
Income Before Tax(64.64M)(36.12M)(13.92M)(8.77M)(8.63M)
Pre-Tax Margin-4784.5%-2673.4%———
Income Tax Expense3.57M163K92K96K90K
Net Income(64.18M)(33.28M)(21.03M)(11.12M)(7.99M)
Net Margin-4750.5%-2463.3%———
EPS (Basic)(1.64)(0.85)(0.54)(0.28)(0.20)
EPS (Diluted)(1.64)(0.85)(0.54)(0.28)(0.20)
Weighted Avg Shares39.02M39.09M39M39.73M40.41M
Weighted Avg Shares (Diluted)39.02M39.09M39M39.73M40.41M

BeyondSpring Inc.

NASDAQ:BYSI

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.